257 related articles for article (PubMed ID: 32092358)
21. Why are immune adverse events so common with checkpoint inhibitor therapy?
Lyubchenko T; Leung DYM; Goleva E
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):608-610. PubMed ID: 33774187
[No Abstract] [Full Text] [Related]
22. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system.
Shi J; Niu J; Shen D; Liu M; Tan Y; Li Y; Huang Y; Cui L; Guan Y; Zhang L
Thorac Cancer; 2020 Feb; 11(2):481-487. PubMed ID: 31823509
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab in the Treatment of Breast Cancer.
Pivot X
N Engl J Med; 2022 Jul; 387(3):273-274. PubMed ID: 35857664
[No Abstract] [Full Text] [Related]
24. Gastrointestinal: Severe gastritis with complete gastric mucosal sloughing.
Nasser R; Fisher Y; Klein A
J Gastroenterol Hepatol; 2021 Oct; 36(10):2639. PubMed ID: 33624341
[No Abstract] [Full Text] [Related]
25. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!
Maria ATJ; Delmas C; Coustal C; Palassin P; Roubille F
Eur J Cancer; 2022 Dec; 177():194-196. PubMed ID: 36809166
[No Abstract] [Full Text] [Related]
27. Laryngeal Tuberculosis in a Patient on Avelumab for Metastatic Nasopharyngeal Carcinoma.
Song JS; Jeffery CC
J Immunother; 2020 Sep; 43(7):222-223. PubMed ID: 32780576
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors: a promising anticancer therapy.
Singh S; Hassan D; Aldawsari HM; Molugulu N; Shukla R; Kesharwani P
Drug Discov Today; 2020 Jan; 25(1):223-229. PubMed ID: 31738877
[TBL] [Abstract][Full Text] [Related]
29. Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab.
Tchapyjnikov D; Borst AJ
J Immunother; 2017 Sep; 40(7):286-288. PubMed ID: 28604555
[TBL] [Abstract][Full Text] [Related]
30. Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
Zhang QJ; Luan JC; Song LB; Cong R; Ji CJ; Zhou X; Xia JD; Song NH
Front Immunol; 2021; 12():657575. PubMed ID: 33936087
[TBL] [Abstract][Full Text] [Related]
31. Visceral Aneurysm Formation and Intraabdominal Hemorrhage Associated with Immune Checkpoint Inhibitor Therapy.
Lee AY; Lam A; Hicks RM; Isikbay M; Heller MB; Sugi MD; Behr S; Kohi MP
J Vasc Interv Radiol; 2021 Jan; 32(1):151-152. PubMed ID: 33277167
[No Abstract] [Full Text] [Related]
32. Unraveling LGALS1 as a Potential Immune Checkpoint and a Predictor of the Response to Anti-PD1 Therapy in Clear Cell Renal Carcinoma.
Li Y; Yang S; Yue H; Yuan D; Li L; Zhao J; Zhao L
Pathol Oncol Res; 2020 Jul; 26(3):1451-1458. PubMed ID: 31428993
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis.
Cappelli LC; Thomas MA; Bingham CO; Shah AA; Darrah E
Immunol Rev; 2020 Mar; 294(1):106-123. PubMed ID: 31930524
[TBL] [Abstract][Full Text] [Related]
34. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
Brahmer JR; Lacchetti C; Thompson JA
J Oncol Pract; 2018 Apr; 14(4):247-249. PubMed ID: 29517954
[No Abstract] [Full Text] [Related]
35. Neurologic complications of immune checkpoint inhibitors.
Fellner A; Makranz C; Lotem M; Bokstein F; Taliansky A; Rosenberg S; Blumenthal DT; Mandel J; Fichman S; Kogan E; Steiner I; Siegal T; Lossos A; Yust-Katz S
J Neurooncol; 2018 May; 137(3):601-609. PubMed ID: 29332184
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitor-Mediated Cardiovascular Disease: The Dark Side of the Monoclonal Anti-Body Therapy against Cancer.
Caiati C; Jirillo E
Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1365-1367. PubMed ID: 37062060
[No Abstract] [Full Text] [Related]
37. Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors.
Hadfield MJ; Mistry H; Pelcovits A; Bansal R; Andrea S; Chergui A; Ramphal K; Austin M; Khurshid H
Am J Clin Oncol; 2023 Apr; 46(4):183-184. PubMed ID: 36959209
[No Abstract] [Full Text] [Related]
38. Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events.
Reese SW; Marchese M; McNabb-Baltar J
Gastroenterology; 2020 Oct; 159(4):1195-1200.e1. PubMed ID: 32681919
[No Abstract] [Full Text] [Related]
39. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
[TBL] [Abstract][Full Text] [Related]
40. A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy.
Murakata Y; Tajiri K
Intern Med; 2022 Jul; 61(14):2099-2100. PubMed ID: 35283387
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
